<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.biomedcentral.com/feeds/mostaccessed/journal?journal=bmcimmunol&amp;quantity=&amp;format=rss&amp;version=">
        <title>BMC Immunology - Most accessed articles</title>
        <link>http://www.biomedcentral.com/bmcimmunol/</link>
        <description>The most accessed research articles published by BMC Immunology</description>
        <dc:date>2009-11-22T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/10/52" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/10/49" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/10/55" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/10/57" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/10/58" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/10/59" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/10/54" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/10/56" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/10/51" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2172/10/53" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.biomedcentral.com/1471-2172/10/52">
        <title>Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays </title>
        <description>Background:
Growing knowledge about cellular interactions in the immune system, including the central role of cytokine networks, has lead to new treatments using monoclonal antibodies that block specific components of the immune system. Systemic cytokine concentrations can serve as surrogate outcome parameters of these interventions to study inflammatory pathways operative in patients in vivo. This is now possible due to novel technologies such as multiplex immunoassays (MIA) that allows detection of multiple cytokines in a single sample. However, apparently trivial underappreciated processes, (sample handling and storage, interference of endogenous plasma proteins) can greatly impact the reliability and reproducibility of cytokine detection.Therefore we set out to investigate several processes that might impact cytokine profiles such as blood collecting tubes, duration of storage, and number of freeze thawing cycles.
Results:
Since under physiological conditions cytokine concentrations normally are low or undetectable we spiked cytokines in the various plasma and serum samples. Overall recoveries ranged between 80-120%. Long time storage showed cytokines are stable for a period up to 2 years of storage at -80&#176;C. After 4 years several cytokines (IL-1&#945;, IL-1&#946;, IL-10, IL-15 and CXCL8) degraded up to 75% or less of baseline values. Furthermore we show that only 2 out of 15 cytokines remained stable after several freeze-thawing cycles. We also demonstrate implementation of an internal control for multiplex cytokine immunoassays.
Conclusion:
All together we show parameters which are essential for measurement of cytokines in the context of clinical trials.</description>
        <link>http://www.biomedcentral.com/1471-2172/10/52</link>
                <dc:creator>Wilco de Jager</dc:creator>
                <dc:creator>Katarzyna Bourcier</dc:creator>
                <dc:creator>Ger Rijkers</dc:creator>
                <dc:creator>Berent Prakken</dc:creator>
                <dc:creator>Vicki Seyfert-Margolis</dc:creator>
                <dc:source>BMC Immunology 2009, 10:52</dc:source>
        <dc:date>2009-09-28T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2172-10-52</dc:identifier>
        <prism:publicationName>BMC Immunology</prism:publicationName>
        <prism:issn>1471-2172</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>52</prism:startingPage>
        <prism:publicationDate>2009-09-28T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2172/10/49">
        <title>Ethanol inhibits LPS-induced signaling and modulates cytokine production in peritoneal macrophages in vivo in a model for binge drinking</title>
        <description>Background:
Previous reports indicate that ethanol, in a binge drinking model in mice, inhibits the production of pro-inflammatory cytokines in vivo. However, the inhibition of signaling through TLR4 has not been investigated in this experimental model in vivo. Considering evidence that signaling can be very different in vitro and in vivo, the present study was conducted to determine if effects of ethanol on TLR4 signaling reported for cells in culture or cells removed from ethanol treated mice and stimulated in culture also occur when ethanol treatment and TLR4 activation occur in vivo.
Results:
Phosphorylated p38, ERK, and c-Jun (nuclear) were quantified with kits or by western blot using samples taken 15, 30, and 60 min after stimulation of peritoneal macrophages with lipopolysaccharide in vivo. Effects of ethanol were assessed by administering ethanol by gavage at 6 g/kg 30 min before administration of lipopolysaccharide (LPS). Cytokine concentrations in the samples of peritoneal lavage fluid and in serum were determined at 1, 2, and 6 hr after lipopolysaccharide administration. All of these data were used to measure the area under the concentration vs time curve, which provided an indication of the overall effects of ethanol in this system. Ethanol suppressed production of most pro-inflammatory cytokines to a similar degree as it inhibited key TLR4 signaling events. However, NF-&#954;B (p65) translocation to the nucleus was not inhibited by ethanol. To determine if NF-&#954;B composed of other subunits was inhibited, transgenic mice with a luciferase reporter were used. This revealed a reproducible inhibition of NF-&#954;B activity, which is consistent with the observed inhibition of cytokines whose expression is known to be NF-&#954;B dependent.
Conclusion:
Overall, the effects of ethanol on signalling in vivo were similar to those reported for in vitro exposure to ethanol and/or lipopolysaccharide. However, inhibition of the activation of NF-&#954;B was not detected as translocation of p65 to the nucleus but was detected using transgenic reporter mice. The observation that ethanol given 24 hr before dosing with LPS modulated production of some cytokines indicates a persistent effect which does not require continued presence of ethanol.</description>
        <link>http://www.biomedcentral.com/1471-2172/10/49</link>
                <dc:creator>Stephen Pruett</dc:creator>
                <dc:creator>Ruping Fan</dc:creator>
                <dc:source>BMC Immunology 2009, 10:49</dc:source>
        <dc:date>2009-09-18T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2172-10-49</dc:identifier>
        <prism:publicationName>BMC Immunology</prism:publicationName>
        <prism:issn>1471-2172</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>49</prism:startingPage>
        <prism:publicationDate>2009-09-18T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2172/10/55">
        <title>Selenium deficiency impairs host innate immune response and induces susceptibility to Listeria monocytogenes infection</title>
        <description>Background:
Susceptibility or resistance to infection with Listeria monocytogenes correlates with Selenium (Se) deficiency in response to infection.
Results:
Se-deficient mouse models of listeriosis were used to study the innate immune response during the course of L. monocytogenes infection. Blood samples from mouse models were used for Se status. The concentration of MDA, SOD, GPx and CAT in blood has revealed that lower Se level exist in Se-deficient mice. Intestine, mesenteric lymph node, liver, spleen and brain from each mouse were to study the bacterial burden in organs. The analysis of cell types of spleen from Se-deficient mice revealed that the ability of the host to elicit a rapid recruitment and activation of systemic innate immune response to infection was to a certain extent compromised under conditions of Se deficiency. The cytokine levels in the serum and cytokine expression levels in the livers from Se-deficient mice revealed that the innate immune response of Se-deficient mice was impaired throughout the course of infection. These results suggest that innate immune response is altered by Se deficiency after infection with L. monocytogenes.
Conclusion:
In conclusion, induced susceptibility of host resistance is associated with an impaired innate immune response following infection with L. monocytogenes in C57BL/6 Se-deficient mice.</description>
        <link>http://www.biomedcentral.com/1471-2172/10/55</link>
                <dc:creator>Chengmin Wang</dc:creator>
                <dc:creator>Haijing Wang</dc:creator>
                <dc:creator>Jing Luo</dc:creator>
                <dc:creator>Yi Hu</dc:creator>
                <dc:creator>Lei Wei</dc:creator>
                <dc:creator>Mingxing Duan</dc:creator>
                <dc:creator>Hongxuan He</dc:creator>
                <dc:source>BMC Immunology 2009, 10:55</dc:source>
        <dc:date>2009-10-24T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2172-10-55</dc:identifier>
        <prism:publicationName>BMC Immunology</prism:publicationName>
        <prism:issn>1471-2172</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>55</prism:startingPage>
        <prism:publicationDate>2009-10-24T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2172/10/57">
        <title>Selenoproteins regulate macrophage invasiveness and extracellular matrix-related gene expression</title>
        <description>Background:
Selenium, a micronutrient whose deficiency in diet causes immune dysfunction and inflammatory disorders, is thought to exert its physiological effects mostly in the form of selenium-containing proteins (selenoproteins). Incorporation of selenium into the amino acid selenocysteine (Sec), and subsequently into selenoproteins is mediated by Sec tRNA[Ser]Sec.
Results:
To define macrophage-specific selenoprotein functions, we generated mice with the Sec tRNA[Ser]Sec gene specifically deleted in myeloid cells. These mutant mice were devoid of the &quot;selenoproteome&quot; in macrophages, yet exhibited largely normal inflammatory responses. However, selenoprotein deficiency led to aberrant expression of extracellular matrix-related genes, and diminished migration of macrophages in a protein gel matrix.
Conclusion:
Selenium status may affect immune defense and tissue homeostasis through its effect on selenoprotein expression and the trafficking of tissue macrophages.</description>
        <link>http://www.biomedcentral.com/1471-2172/10/57</link>
                <dc:creator>Bradley Carlson</dc:creator>
                <dc:creator>Min-Hyuk Yoo</dc:creator>
                <dc:creator>Yasuyo Sano</dc:creator>
                <dc:creator>Aniruddha Sengupta</dc:creator>
                <dc:creator>Jin Young Kim</dc:creator>
                <dc:creator>Robert Irons</dc:creator>
                <dc:creator>Vadim Gladyshev</dc:creator>
                <dc:creator>Dolph Hatfield</dc:creator>
                <dc:creator>Jin Mo Park</dc:creator>
                <dc:source>BMC Immunology 2009, 10:57</dc:source>
        <dc:date>2009-10-28T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2172-10-57</dc:identifier>
        <prism:publicationName>BMC Immunology</prism:publicationName>
        <prism:issn>1471-2172</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>57</prism:startingPage>
        <prism:publicationDate>2009-10-28T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2172/10/58">
        <title>Derivation and validation of murine histologic alterations resembling asthma, with two proposed histologic grade parameters.</title>
        <description>Background:
The objective was to define murine histologic alterations resembling asthma in a BALB/c OVA model and to suggest grading criteria. Identified were six salient histologic findings in lungs with putative allergic inflammation: 1) bronchoarterial space inflammation; 2) peri-venular inflammation; 3) inflammation about amuscular blood vessels; 4) inter-alveolar space inflammation, not about capillaries; 5) pleural inflammation; and 6) eosinophils within the inflammatory aggregates. An initial study comprised six groups of twelve mice each: 1) stressed, control; 2) stressed, sensitized; 3) stressed, challenged; 4) not physically stressed, control; 5) not physically stressed, sensitized; 6) not physically stressed, challenged. A second study comprised four experimental groups of twenty mice each: 1) stressed, control; 2) stressed, challenged; 3) not physically stressed, control; 4) not physically stressed, challenged. A third study evaluated two grading criteria, 1) the proportion of non-tracheal respiratory passages with inflammatory aggregates and 2) mitoses in the largest two non-tracheal respiratory passages, in five groups of five mice each, evaluated at different times after the last exposure.
Results:
The first study suggested the six histological findings might reliably indicate the presence of alterations resembling asthma: whereas 82.4% of mice with a complete response had detectable interleukin (IL)-5, only 3.8% of mice without one did; whereas 77.8% of mice with a complete response were challenged mice, only 6.7% of mice without complete responses were. The second study revealed that the six histological findings provided a definition that was 97.4% sensitive and 100% specific. The third study found that the odds of a bronchial passage&apos;s having inflammation declined 1) when mitoses were present (OR = 0.73, 0.60 - 0.90), and 2) with one day increased time (OR = 0.75, 0.65 - 0.86).
Conclusion:
A definition of murine histologic alterations resembling asthma in the BALB/c OVA mouse was developed and validated. The definition will be of use in experiments involving this model to ensure that all mice said to have undergone an asthmatic attack did indeed reveal allergic pulmonary inflammation. Proposed grading criteria should be further evaluated with additional studies using physiologic measures of attack severity and increased airway resistance.</description>
        <link>http://www.biomedcentral.com/1471-2172/10/58</link>
                <dc:creator>Mitchell Wachtel</dc:creator>
                <dc:creator>Goutam Shome</dc:creator>
                <dc:creator>Mhairi Sutherland</dc:creator>
                <dc:creator>John McGlone</dc:creator>
                <dc:source>BMC Immunology 2009, 10:58</dc:source>
        <dc:date>2009-10-30T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2172-10-58</dc:identifier>
        <prism:publicationName>BMC Immunology</prism:publicationName>
        <prism:issn>1471-2172</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>58</prism:startingPage>
        <prism:publicationDate>2009-10-30T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2172/10/59">
        <title>Induction of granzyme B expression in T-cell receptor/CD28 stimulated human regulatory T cells is suppressed by inhibitors of the PI3K-mTOR pathway.
</title>
        <description>Background:
Regulatory T cells (Tregs) can employ a cell contact- and granzyme B-dependent mechanism to mediate suppression of bystander T and B cells. Murine studies indicate that granzyme B is involved in the Treg-mediated suppression of anti-tumor immunity in the tumor microenvironment and in the Treg-mediated maintenance of allograft survival. In spite of its central importance, a detailed study of granzyme B expression patterns in human Tregs has not been performed.
Results:
Our data demonstrated that natural Tregs freshly isolated from the peripheral blood of normal adults lacked granzyme B expression. Tregs subjected to prolonged TCR and CD28 triggering, in the presence of IL-2, expressed high levels of granzyme B but CD3 stimulation alone or IL-2 treatment alone failed to induce granzyme B. Treatment of Tregs with the mammalian target of rapamycin (mTOR) inhibitor, rapamycin or the PI3 kinase (PI3K) inhibitor LY294002 markedly suppressed granzyme B expression. However, neither rapamycin, as previously reported by others, nor LY294002 inhibited Treg proliferation or induced significant cell death in TCR/CD28/IL-2 stimulated cells. The proliferation rate of Tregs was markedly higher than that of CD4+ conventional T cells in the setting of rapamycin treatment. Tregs expanded by CD3/CD28/IL-2 stimulation without rapamycin demonstrated increased in vitro cytotoxic activity compared to Tregs expanded in the presence of rapamycin in both short term (6 hours) and long term (48 hours) cytotoxicity assays.
Conclusion:
TCR/CD28 mediated activation of the PI3K-mTOR pathway is important for granyzme B expression but not proliferation in regulatory T cells. These findings may indicate that suppressive mechanisms other than granzyme B are utilized by rapamycin-expanded Tregs.</description>
        <link>http://www.biomedcentral.com/1471-2172/10/59</link>
                <dc:creator>Olga Efimova</dc:creator>
                <dc:creator>Todd Kelley</dc:creator>
                <dc:source>BMC Immunology 2009, 10:59</dc:source>
        <dc:date>2009-11-22T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2172-10-59</dc:identifier>
        <prism:publicationName>BMC Immunology</prism:publicationName>
        <prism:issn>1471-2172</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>59</prism:startingPage>
        <prism:publicationDate>2009-11-22T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2172/10/54">
        <title>Modulation of pathogen-induced CCL20 secretion from human HT-29 intestinal epithelial cells by commensal bacteria</title>
        <description>Background:
Human intestinal epithelial cells (IECs) secrete the chemokine CCL20 in response to infection by various enteropathogenic bacteria or exposure to bacterial flagellin. CCL20 recruits immature dendritic cells and lymphocytes to target sites. Here we investigated IEC responses to various pathogenic and commensal bacteria as well as the modulatory effects of commensal bacteria on pathogen-induced CCL20 secretion. HT-29 human IECs were incubated with commensal bacteria (Bifidobacterium infantis or Lactobacillus salivarius), or with Salmonella typhimurium, its flagellin, Clostridium difficile, Mycobacterium paratuberculosis, or Mycobacterium smegmatis for varying times. In some studies, HT-29 cells were pre-treated with a commensal strain for 2 hr prior to infection or flagellin stimulation. CCL20 and interleukin (IL)-8 secretion and nuclear factor (NF)-&#954;B activation were measured using enzyme-linked immunosorbent assays.
Results:
Compared to untreated cells, S. typhimurium, C. difficile, M. paratuberculosis, and flagellin activated NF-&#954;B and stimulated significant secretion of CCL20 and IL-8 by HT-29 cells. Conversely, B. infantis, L. salivarius or M. smegmatis did not activate NF-&#954;B or augment CCL20 or IL-8 production. Treatment with B. infantis, but not L. salivarius, dose-dependently inhibited the baseline secretion of CCL20. In cells pre-treated with B. infantis, C. difficile-, S. typhimurium-, and flagellin-induced CCL20 were significantly attenuated. B. infantis did not limit M. Paratuberculosis-induced CCL20 secretion.
Conclusion:
This study is the first to demonstrate that a commensal strain can attenuate CCL20 secretion in HT-29 IECs. Collectively, the data indicate that M. paratuberculosis may mediate mucosal damage and that B. infantis can exert immunomodulatory effects on IECs that mediate host responses to flagellin and flagellated enteric pathogens.</description>
        <link>http://www.biomedcentral.com/1471-2172/10/54</link>
                <dc:creator>Shomik Sibartie</dc:creator>
                <dc:creator>Ann O'Hara</dc:creator>
                <dc:creator>Jude Ryan</dc:creator>
                <dc:creator>Aine Fanning</dc:creator>
                <dc:creator>Jim O'Mahony</dc:creator>
                <dc:creator>Shaun O'Neill</dc:creator>
                <dc:creator>Barbara Sheil</dc:creator>
                <dc:creator>Liam O'Mahony</dc:creator>
                <dc:creator>Fergus Shanahan</dc:creator>
                <dc:source>BMC Immunology 2009, 10:54</dc:source>
        <dc:date>2009-10-08T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2172-10-54</dc:identifier>
        <prism:publicationName>BMC Immunology</prism:publicationName>
        <prism:issn>1471-2172</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>54</prism:startingPage>
        <prism:publicationDate>2009-10-08T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2172/10/56">
        <title>The inhibitory receptor LILRB4 (ILT3) modulates antigen presenting cell phenotype and, along with LILRB2 (ILT4), is upregulated in response to Salmonella infection </title>
        <description>Background:
Leukocyte Ig-like receptors (LILR) are a family of innate immune receptors with immunomodulatory functions. High-level expression of the receptors LILRB2 (ILT4) and LILRB4 (ILT3) is a feature of tolerogenic antigen presenting cells and has been observed in cancer and transplant situations. There are relatively few studies regarding these receptors in the context of infection and it is not yet clear how LILRB4 exerts its inhibitory effects.
Results:
We studied the effects of LILRB4 ligation on antigen presenting cell phenotype, and the expression of LILRB2 and LILRB4 on Salmonella-infected antigen presenting cells. Ligation of LILRB4 throughout in vitro culture of dendritic cells led to an upregulation of the co-stimulatory protein CD86. Alterations in the production of IL-8 and IL-10 by LILRB4-ligated macrophages were also observed. Infection with Salmonella typhimurium or TLR stimulation with Salmonella components led to an upregulation of LILRB2 and LILRB4.
Conclusion:
Our results indicate that the inhibitory effects of LILRB4 do not result from a failure to upregulate co-stimulatory proteins. In addition to the high level expression that can render antigen presenting cells tolerogenic, there may be a role for lower level expression and activity of LILRB2 and LILRB4 in response to TLR signalling during an immune response to bacterial infection.</description>
        <link>http://www.biomedcentral.com/1471-2172/10/56</link>
                <dc:creator>Damien Brown</dc:creator>
                <dc:creator>Des Jones</dc:creator>
                <dc:creator>Katie Anderson</dc:creator>
                <dc:creator>Nicolas Lapaque</dc:creator>
                <dc:creator>Robin Buerki</dc:creator>
                <dc:creator>John Trowsdale</dc:creator>
                <dc:creator>Rachel Allen</dc:creator>
                <dc:source>BMC Immunology 2009, 10:56</dc:source>
        <dc:date>2009-10-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2172-10-56</dc:identifier>
        <prism:publicationName>BMC Immunology</prism:publicationName>
        <prism:issn>1471-2172</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>56</prism:startingPage>
        <prism:publicationDate>2009-10-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2172/10/51">
        <title>Biochemical analysis of CTLA-4 immunoreactive material from human blood</title>
        <description>Background:
CTLA-4 was initially described as a membrane-bound molecule that inhibited lymphocyte activation by interacting with B7.1 and B7.2 molecules on antigen presenting cells. Alternative splicing of mRNA encoding the CTLA-4 receptor leads to the production of a molecule (sCTLA-4) that lacks a membrane anchor and is therefore secreted into the extracellular space. Despite studies finding that people with autoimmune disease more frequently express high levels of sCTLA-4 in their blood than apparently healthy people, the significance of these findings is unclear.
Methods:
Molecules isolated from blood using CTLA-4 specific antibodies were analyzed with ligand binding assays, mass spectroscopy, and biochemical fractionation in an effort to increase our understanding of CTLA-4 immunoreactive material.
Results:
Mass spectroscopy analysis of the molecules recognized by multiple CTLA-4-specific antibodies failed to identify any CTLA-4 protein. Even though these molecules bind to the CTLA-4 receptors B7.1 and B7.2, they also exhibit properties common to immunoglobulins.
Conclusion:
We have identified molecules in blood that are recognized by CTLA-4 specific antibodies but also exhibit properties of immunoglobulins. Our data indicates that what has been called sCTLA-4 is not a direct product of the CTLA-4 gene, and that the CTLA-4 protein is not part of this molecule. These results may explain why the relationship of sCTLA-4 to immune system activity has been difficult to elucidate.</description>
        <link>http://www.biomedcentral.com/1471-2172/10/51</link>
                <dc:creator>Matt Tector</dc:creator>
                <dc:creator>Bhupendra Khatri</dc:creator>
                <dc:creator>Karen Kozinski</dc:creator>
                <dc:creator>Kate Dennert</dc:creator>
                <dc:creator>Martin Oaks</dc:creator>
                <dc:source>BMC Immunology 2009, 10:51</dc:source>
        <dc:date>2009-09-22T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2172-10-51</dc:identifier>
        <prism:publicationName>BMC Immunology</prism:publicationName>
        <prism:issn>1471-2172</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>51</prism:startingPage>
        <prism:publicationDate>2009-09-22T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2172/10/53">
        <title>Identification of SH3 domain interaction partners of human FasL (CD178) by phage display screening</title>
        <description>Background -Fas ligand is a cytotoxic effector molecule of T and NK cells which is characterized by an intracellular N-terminal polyproline region that serves as a docking site for SH3 and WW domain proteins. Several previously described Fas ligand-interacting SH3 domain proteins turned out to be crucial for the regulation of storage, expression and function of the death factor. Recent observations, however, indicate that Fas ligand is also subject to posttranslational modifications including shedding and intramembrane proteolysis. This results in the generation of short intracellular fragments that might either be degraded or translocate to the nucleus to influence transcription. So far, protein-protein interactions that specifically regulate the fate of the intracellular fragments have not been identified.Results -In order to further define the SH3 domain interactome of the intracellular region of Fas ligand, we now screened a human SH3 domain phage display library. In addition to known SH3 domains mediating binding to the Fas ligand proline-rich domain, we were able to identify a number of additional SH3 domains that might also associate with FasL. Potential functional implications of the new binding proteins for the death factor&apos;s biology are discussed. For Tec kinases and sorting nexins, the observed interactions were verified in cellular systems by pulldown experiments.Conclusion -We provide an extended list of putative Fas ligand interaction partners, confirming previously identified interactions, but also introducing several novel SH3 domain proteins that might be important regulators of Fas ligand function.</description>
        <link>http://www.biomedcentral.com/1471-2172/10/53</link>
                <dc:creator>Matthias Voss</dc:creator>
                <dc:creator>Marcus Lettau</dc:creator>
                <dc:creator>Ottmar Janssen</dc:creator>
                <dc:source>BMC Immunology 2009, 10:53</dc:source>
        <dc:date>2009-10-06T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2172-10-53</dc:identifier>
        <prism:publicationName>BMC Immunology</prism:publicationName>
        <prism:issn>1471-2172</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>53</prism:startingPage>
        <prism:publicationDate>2009-10-06T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
